Our "Behind the Desk" interview series is back again and we are pleased to introduce you to Evita Rodrigues, Assistant Director for Licensing and Procurement. When joining the team this past April, Evita brought to the library a background of over 10 years in client-facing roles. She has worked to foster relationships with notable universities, as well as large and recognizable enterprise organizations. Let's learn more about Evita!
What were you doing before coming to Levy Library?
I was responsible for the full life cycle of implementing and managing intranets for large enterprise organizations. This included providing guidance on how to successfully structure their digital workspace in accordance with their organizational hierarchy. I also aided in identifying the most pressing needs for information and engagement.
Describe the duties and responsibilities of your job.
I’m primarily responsible for the purchase and renewal of all electronic resources. This involves active communication with all vendors to ensure the timely completion of all renewals to safeguard against disruption of services. I plan to develop strategies on better management of resources, in order to make more informed choices for retention of services based on adequate assessments of usage statistics and overall needs.
What is the most challenging aspect of your job?
It’s very challenging to get responses from vendors, so I’m constantly needing to follow-up, which has now earned me the pseudo title of follow-up queen.
What is the most rewarding aspect of your job?
Being able to contribute, in a very indirect way, to the overall knowledge being disseminated which only serves to enhance the value of the library.
What are your interests outside of work?
I’ve always found photography and hiking to be greatly therapeutic, especially when combined. I also consider myself a student of life and enjoy learning new things every day.
Favorite quote:
“The past is a lighthouse, not a port.” – Russian Proverb
If you see Evita around the 11th floor, be sure to say hello!
Each month Levy Library showcases the achievements of Mount Sinai faculty and researchers by highlighting an article and its altmetrics. Altmetrics are alternative measures of impact that capture non-traditional data like abstract views, article downloads, and social media activity. Our altmetrics data is provided by the PlumX platform.
This month we highlight: Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. This article was written in part by Roxana Mehran, Professor of Medicine, Cardiology, and Population Health Science and Policy.
Citation
The New England journal of medicine, ISSN: 1533-4406, Vol: 380, Issue: 16, Page: 1509-1524
Background
Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear.
Methods
In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events.
Results
Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P=0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group.
Conclusions
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400. opens in new tab.)
View the PlumX article profile